Dr. Du has 20 years of experience in non-clinical efficacy and safety evaluation of drugs and providing strategic guidance for Investigational new drug, IND application. She joined EdiGene in July 2023.

Prior to EdiGene, Dr. Du worked at SAFE Pharmaceutical, JOINN (Beijing), and Harbin Medical University Cancer Institute. She has completed successfully non-clinical evaluation for various innovative drugs, including chemicals, macromolecule drugs, new cells and gene therapy drugs. Especially, she has led a lot of pharmacology and safety evaluation projects, established an evaluation platform capable of conducting in vitro and in vivo efficacy and mechanism studies, pharmacokinetic distribution studies, and safety studies for innovative CGT products during the period working in JOINN and SAFE, which has completed the IND submission for nearly a hundred candidates. Dr. Du also participated in the compilation of the "Non-clinical Evaluation Study of CGT Products".

Dr. Du holds a bachelor's degree in clinical medicine and a master's degree in pharmacology from Harbin Medical University, as well as a Ph.D. in biochemistry and molecular biology from Chinese Academy of Sciences.